Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

l interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=P9XDCERPG.

To access the live conference call via phone, dial 1-888-713-4211. International callers may access the live call by dialing 1-617-213-4864. The reference number to enter the call is 47115180.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 1-888-286-8010 for domestic callers or 1-617-801-6888 for international callers. The reference number to enter the replay of the call is 41081227.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute trea
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... Anderson , president and chief executive officer, will present ... September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may be ... will be available shortly after conclusion of the presentation ...
(Date:9/2/2015)... , September 2, 2015 ... Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben zu ... vom Rare Genomics Institute. Biovista unterstützt ... Medikamenten für die Behandlung anderer Krankheiten als denen, ... Steven Laffoon und sein Team bei der ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... been closely following the progress of the Health Insurance ... for the last eight months. You can understand that since ... I have my own special interest at stake. I am ... yet very difficult and dangerous mandate. , ,More important ...
... 9/11 era should be everyone's goal, whether they are ... business with mission-critical network needs. This endeavor should transcend ... globally is a matter of national defense as well ... company, Neutral Tandem, Inc ., has been assembling ...
... by the Circuit Court of Wisconsin in Milwaukee ... businesses that acquired Microsoft software over a ... million back to them as part of a proposed ... , ,The notices are the result of a proposed ...
Cached Biology Technology:Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4Obstructionists block network routing diversity 2Obstructionists block network routing diversity 3Obstructionists block network routing diversity 4Microsoft to distribute $224M as part of settlement 2
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent analysis ... with the 2015 African Biometrics Company of the Year Award. ... substantial commercial success in Africa . It ... where it has implemented one of the largest biometric mass ... well as the Central Bank of Nigeria ...
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International ... it has entered into a Definitive Agreement to ... of iris authentication market leader EyeLock through an ... will have a controlling interest in the acquiring ... to completion of due diligence.  Expanding on its ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... team has identified a key enzyme responsible for triggering ... according to new study findings published online this week ... Virginia Commonwealth University, the Hospital for Special Surgery and ... stage for development of new strategies and target therapies ...
... Johns Hopkins scientists have interfered with the brain's ability to ... report, to be published in the latest issue of the ... of May 1, is based on the identification of a ... weight. , According to the researchers, the CPT1c gene ...
... scientists has reconstructed the DNA sequence of a 5-million-year-old retrovirus ... The retrovirus--named Phoenix--is the ancestor of a large family ... role in cancer. The study, which is the first ... the human genome, is considered a breakthrough for the field ...
Cached Biology News:Key molecular signaling switch involved in allergic disease identified 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 3Scientists resuscitate a 5 million-year-old retrovirus 2
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Biology Products: